Gaboxadol

Last updated

Gaboxadol
Gaboxadol.svg
Clinical data
Other namesGBX; THIP; 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol; Lu-2-030; Lu-02-030; MK-0928; MK0928; OV101; OV-101
Routes of
administration 		Oral [1] [2]
Drug class GABAA receptor agonist; Sedative; Hypnotic; Central depressant; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Bioavailability 83–96% (absorption) [3]
Protein binding <2% [3] [4]
Metabolism Glucuronidation mainly via UGT1A9 [3] [5]
Metabolites Gaboxadol-O-glucuronide [3]
Onset of action 20–60 minutes (peak) [3] [6] [5]
Elimination half-life 1.5–2.0 hours [7] [8] [9]
Excretion Urine (84–93%; mainly unchanged, partially glucuronidated (34%)) [3] [4] [5] [10]
Identifiers
  • 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.059.039 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C6H8N2O2
Molar mass 140.142 g·mol−1
3D model (JSmol)
  • O=C1/C2=C(\ON1)CNCC2
  • InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9) Yes check.svgY
  • Key:ZXRVKCBLGJOCEE-UHFFFAOYSA-N Yes check.svgY
   (verify)

Gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) and by its former developmental code names Lu-2-030, MK-0928, and OV101, is a GABAA receptor agonist related to muscimol which was investigated for the treatment of insomnia and other conditions like Angelman syndrome but was never marketed. [2] [11] [1] [12] [13] At lower doses, the drug has sedative and hypnotic effects, and at higher doses, it produces hallucinogenic effects. [1] [14] [13] It is taken orally. [1] [2]

Contents

The drug acts as a potent and selective partial agonist of the GABAA receptor, the major signaling receptor of the inhibitory endogenous neurotransmitter γ-aminobutyric acid (GABA). [1] [11] However, it acts as a preferential supra-maximal agonist at extrasynaptic δ subunit-containing GABAA receptors. [15] [11] In contrast to GABAA receptor positive allosteric modulators like benzodiazepines and Z drugs, gaboxadol is an orthosteric agonist of the GABAA receptor, acting on the same site as GABA rather than at an allosteric regulatory site. [16] [1] [11] As a result, gaboxadol has differing effects from benzodiazepines and related drugs. [16] [1] [11] [15] Gaboxadol is a conformationally constrained synthetic analogue of GABA and of muscimol, an alkaloid and hallucinogen found in Amanita muscaria (fly agaric) mushrooms. [1] [11] [17] [18] It has greatly improved drug-like properties compared to these compounds. [11] [17] [19] [13]

Gaboxadol was first described by Povl Krogsgaard-Larsen and colleagues in 1977. [1] [13] [20] It was assessed in clinical studies for various uses in the 1980s, but was not found to be useful. [11] [15] [14] [13] In the 1990s and 2000s, gaboxadol was repurposed for treatment of insomnia and completed phase 3 clinical trials for this indication. [1] [14] [15] [21] However, development was discontinued for safety and effectiveness reasons in 2007. [2] [3] [15] [13] Subsequently, gaboxadol was repurposed again for treatment of Angelman syndrome and fragile X syndrome, but development for these uses was discontinued as well. [2] [12] [22] [23]

Use and effects

Gaboxadol produces sedative and hypnotic effects at lower doses and hallucinogenic effects at higher doses. [1] [14] [13] It has also been reported to produce mood elevation [24] and sometimes euphoria. [14] [25]

Hypnotic effects

Gaboxadol has been assessed in clinical studies at doses ranging from 10 to 160 mg. [11] [13] It was studied in clinical trials for treatment of insomnia specifically at doses of 5 to 20 mg. [1] [16] The drug's effects at a dose of 10 mg were anecdotally described by Povl Krogsgaard-Larsen as similar to having drunk two or three beers. [13] It was found to be limitedly effective for improving sleep at doses of 5 and 10 mg, but was more effective at doses of 15 to 20 mg. [16] [15] [1] [26] Higher doses for insomnia were precluded by a narrow therapeutic index and high rates of psychiatric adverse effects at such doses. [26] [27]

Gaboxadol has been found to decrease sleep onset latency, increase sleep duration, increase slow wave sleep (SWS) and slow wave activity (SWA), preserve sleep architecture, not affect REM sleep, and improve subjective sleep quality and daytime functioning. [11] [1] [28] [29] The drug was found to allow people to fall asleep and stay asleep whilst exposed to continuous recorded stream of road traffic noise, a model of transient insomnia. [13] [30] Gaboxadol's hypnotic effects have been found to be stronger in women than in men. [28] [21] On the other hand, SWS decreases with age, especially in men, and gaboxadol was found to substantially compensate for the reduction in SWS in elderly men. [11] [31] [13] [32] The drug was also studied in experimental sleep restriction and was found to increase SWS and improve daytime functioning, for instance symptoms of sleepiness and fatigue, despite equal total sleep durations. [29] [33]

There was no tolerance to the hypnotic effects of gaboxadol after 5 days of repeated administration in animals. [11] [34] Similarly, it maintained effectiveness in short-term clinical studies in humans. [21] However, gaboxadol was subsequently found to be initially effective in improving sleep in insomnia but to not maintain its benefits after 1 month. [16] [35] In addition, gaboxadol showed mixed effectiveness at the assessed doses of 10 to 15 mg in two large 3-month clinical trials for insomnia. [3] [21]

The effects of gaboxadol on sleep differ from those of widely used GABAA receptor positive allosteric modulators like benzodiazepines and Z drugs, which have been found to disrupt rather than enhance SWS and SWA despite improving sleep onset and duration. [19] [11] [36] [17] In addition, unlike such agents, gaboxadol caused no rebound insomnia on discontinuation and produced no next-day residual symptoms. [16] [15] [37] While dissimilar from GABAA receptor positive allosteric modulators, the effects of gaboxadol on sleep are similar to those of the related GABAA receptor agonist muscimol and of the GABA reuptake inhibitor tiagabine. [19] [31] [17] [11] [38]

Although gaboxadol was found to be effective in the treatment of insomnia and uniquely able to improve SWS, it was found to have less robust effects on traditional hypnotic effectiveness measures like sleep onset and duration at the evaluated doses compared to zolpidem. [29] [39] [40] In addition, it was more effective for improving sleep maintenance than for improving sleep onset. [21]

Gaboxadol was developed for the treatment of insomnia, in which disruption of SWS is not the main feature. [16] [39] The effects of gaboxadol in people with sleeping problems specifically involving impaired SWS have largely not been studied and are unknown. [16] [40]

Hallucinogenic effects

Gaboxadol was assessed at supratherapeutic doses of 30 to 45 mg and compared to the Z drug zolpidem in drug users during its development for treatment of insomnia. [13] [21] [25] At these doses, gaboxadol produced euphoria and hallucinogenic effects such as dissociation, perceptual changes, and hallucinations. [13] [21] [25] [26] The rates of such psychiatric adverse effects were 15% with placebo, 38% with 15 mg, 72% with 30 mg, and 88% with 45 mg gaboxadol. [27] It showed less euphoria and misuse potential, more negative and dissociative effects, and fewer sedative effects than zolpidem in these individuals. [25] At a dose of 60 mg twice daily in an early study, gaboxadol was described as producing effects including dizziness, vomiting, somnolence, and strong sedation. [11] High doses of gaboxadol have also been reported to produce delirium, amnesia, and loss of consciousness. [13]

According to journalist and scientist Hamilton Morris, the drug can produce strong hallucinogenic effects at high doses similarly to muscimol, with hallucinogenic effects starting at around doses of 30 or 40 mg and powerful hallucinogenic effects occurring at a dose of about 65 mg of the zwitterion. [41] [42] [43] [44] [45] Morris has described hallucinogenic effects he experienced with gaboxadol as follows: [46] [13]

"The next night I increased the dose to 35mg sublingually, and it was then that gaboxadol's relationship to muscimol became manifest. In my darkened bedroom I could hear otherworldly music emanating from the motor of a box fan, the white-noise buzzing slowing, taking on the character of an electric viola, the room’s various shadows animated by strange movements, as if cast by a flickering candle — but none of this proved distracting. Once again I fell into an all-consuming slumber." [46] [13]

He has also reported other qualitative accounts of the hallucinogenic effects of gaboxadol. [43] [44] [45] Morris has stated that gaboxadol is every bit as powerful as a hallucinogen as serotonergic psychedelics like ayahuasca, but is qualitatively completely different. [45] [44]

Side effects

Side effects of gaboxadol include dizziness, sedation, somnolence, headache, nausea, vomiting, and tachycardia, among others. [11] [47] [27] [48] [26] [8] It has also been reported to produce giddiness, depersonalization, impaired concentration, and bradycardia. [8] In clinical studies for insomnia, gaboxadol has been found to be generally well-tolerated for up to 12 months. [21] At high doses, it can produce hallucinogenic effects and delirium. [13] [21] [25] [8]

Interactions

Gaboxadol is metabolized exclusively via glucuronidation and is not appreciated metabolized by cytochrome P450 enzymes, and hence would not be expected to interact with cytochrome P450 inhibitors or inducers. [6]

In contrast to the case of γ-aminobutyric acid (GABA) and muscimol, the binding of gaboxadol to the GABAA receptor does not appear to be stimulated by the benzodiazepine and GABAA receptor positive allosteric modulator diazepam in vitro . [17] [49] In addition, gaboxadol did not show synergistic effects in combination with alcohol or benzodiazepines in vitro or in vivo in animals. [50] [51] [52]

Pharmacology

Pharmacodynamics

Gaboxadol acts as a potent and selective GABAA receptor partial agonist. [1] [11] In contrast to GABAA receptor positive allosteric modulators like benzodiazepines, Z drugs, barbiturates, and alcohol, gaboxadol is an agonist of the orthosteric site of the GABAA receptor and the same site that the neurotransmitter γ-aminobutyric acid binds to and activates. [1] [11] Whereas the related GABAA receptor agonist muscimol is a highly potent partial agonist of the GABAA-ρ receptor (GABAC receptor), gaboxadol is a moderately potent antagonist of this receptor. [17] [53] Unlike muscimol, it is not also a GABA reuptake inhibitor to any extent, and it does not inhibit the enzyme GABA transaminase (GABA-T). [54]

The drug shows functional selectivity at the GABAA receptor relative to GABA itself, activating GABAA receptors of different α subunit compositions with varying efficacies. [55] [56] Its Emax Tooltip maximal efficacy values at GABAA receptors were approximately 71% at α1 subunit-containing receptors, 98% at α2 subunit-containing receptors, 54% at α3 subunit-containing receptors, 40% at α4 subunit-containing receptors, 99% at α5 subunit-containing receptors, and 96% at α6 subunit-containing receptors. [55] [56] Moreover, gaboxadol has been found to act as a supra-maximal agonist at α4β3δ subunit-containing GABAA receptors, low-potency agonist at α1β3γ2 subunit-containing receptors, and partial agonist at α4β3γ subunit-containing receptors. [57] [58] [59] Its affinity for extrasynaptic α4β3δ subunit-containing GABAA receptors is 10-fold greater than for other subtypes. [60] Gaboxadol has a unique affinity for extrasynaptic α4β3δ subunit-containing GABAA receptors, which mediate tonic inhibition and are typically activated by ambient, low levels of GABA in the extrasynaptic space. [61] The supra-maximal efficacy of gabaxadol at α4β3δ subunit-containing GABAA receptors has been attributed to an increase in the duration and frequency of channel openings relative to GABA. [59] Mice with the GABAA receptor δ subunit knocked out are unresponsive to the hypnotic effects of gaboxadol. [15] [62] Because of its preferential agonism of extrasynaptic GABAA receptors, gaboxadol has been referred to as a "selective extrasynaptic GABAA agonist" or "SEGA". [63] [38] In contrast to gaboxadol, benzodiazepines and nonbenzodiazepines do not activate δ subunit-containing GABAA receptors. [15] [6] On the other hand, alcohol is known to selectively potentiate δ subunit-containing extrasynaptic GABAA receptors analogously to gaboxadol. [64] [65] [66] In addition, neurosteroids and propofol act on extrasynaptic δ subunit-containing GABAA receptors. [15] [67] [11]

Gaboxadol shows 25- to 40-fold lower potency as a GABAA receptor agonist than muscimol in in vitro studies. [68] Compared to muscimol, gaboxadol binds less potently to α4β3δ subunit-containing GABAA receptors (EC50 Tooltip half-maximal effective concentration = 0.2 μM vs. 13 μM), but is capable of evoking a greater maximum response (Emax Tooltip maximal efficacy = 120% vs. 224%). [59] Although gaboxadol is far less potent than muscimol in vitro, it is only about 3 times less potency than muscimol in rodents in vivo . [69] [68] This is attributed mainly to gaboxadol's much greater ability to cross the blood–brain barrier than muscimol. [68] However, it appears to be due to gaboxadol levels being several-fold higher than levels of muscimol with systemic administration of the same doses as well. [70] Gaboxadol is also more selective than muscimol and has been said by Povl Krogsgaard-Larsen to be much less toxic in comparison. [55] [19] [71] [13]

In animals, gaboxadol has been found to produce sedation, hypnotic effects, motor impairment, muscle relaxation, hypolocomotion, anxiolytic-like effects, antidepressant-like effects, analgesic effects, and anticonvulsant effects. [1] [38] [54] [72] In rodent drug discrimination studies, gaboxadol has been found to fully generalize with muscimol. [38] [73] However, gaboxadol, GABAA receptor positive allosteric modulators like benzodiazepines and Z drugs, and the GABA reuptake inhibitor tiagabine all do not generalize between each other, suggesting that their interoceptive effects are different. [16] [11] [38] Similarly, gaboxadol did not generalize with the neurosteroid pregnanolone. [38] On the other hand, gaboxadol has shown partial generalization with the barbiturate pentobarbital. [38] Gaboxadol does not produce self-administration or conditioned place preference in rodents or baboons, suggesting that it lacks rewarding or reinforcing effects and has low addictive potential. [74] [75] This is in contrast to benzodiazepines like diazepam. [74] [75]

Pharmacokinetics

Absorption

The absorption of gaboxadol is rapid and almost complete with oral administration (83–96%). [3] [4] [7] [10] It is a zwitterionic compound and its absorption involves active transport via intestinal transporters such as the proton-coupled amino acid transporter 1 (PAT-1). [3] [76] Coadministration of PAT-1 inhibitors like tryptophan or 5-hydroxytryptophan (5-HTP) has been found to decrease the absorptive permeability of gaboxadol by 53 to 89%. [3] [77] [78] However, they may simply delay the absorption of gaboxadol and decrease peak levels. [3] In contrast to the case of the PAT-1, the drug is not a substrate of the proton-coupled di-/tripeptide transporter (PepT-1). [3] Peak levels of gaboxadol are reached 15 to 60 minutes after an oral dose. [3] [6] [5]

Distribution

The distribution of gaboxadol has been studied in rodents. [70] It penetrates the blood–brain barrier and hence is centrally active unlike γ-aminobutyric acid (GABA). [11] [55] [8] The drug enters the brain in amounts that are 30 to 100 times higher than those of muscimol given at the same dose in rodents and hence shows greater blood–brain barrier permeability in comparison. [70] In addition, whereas 90% of the muscimol in the brain is in the form of metabolites in rodents, 80% of the gaboxadol in the brain is in unchanged form. [70] It is unknown which transporters are involved in the transport of gaboxadol across the blood–brain barrier or if it simply crosses into the brain via passive diffusion, although the latter may be more likely. [3] [79] The drug is distributed unevenly in the brain in rodents. [70] The plasma protein binding of gaboxadol in humans is very low at less than 2%. [3] [4]

Metabolism

Gaboxadol is metabolized by O-glucuronidation mainly via the enzyme UGT1A9 into gaboxadol-O-glucuronide. [3] To a lesser extent, UGT1A6, UGT1A7, and UGT1A8 also catalyze the formation of this metabolite. [4] Unlike muscimol, gaboxadol is not a substrate for GABA transaminase (GABA-T) and does not undergo metabolic transamination. [70] It is said to be more resistant to metabolism than muscimol. [55] [71] Gaboxadol-O-glucuronide is the only metabolite of gaboxadol formed in significant amounts. [6] Gaboxadol is not metabolized by the cytochrome P450 system. [6]

Elimination

Gaboxadol is excreted in urine (83–94%) mainly unchanged and partially as gaboxadol-O-glucuronide (34%). [3] [4] [6] [5] [10] It is taken up from blood into the kidneys via the organic anion transporter OAT1 (SLC22A6), while the glucuronide is effluxed into urine via the multidrug resistance protein MRP4 (ABCC4). [3] [4] The drug has an elimination half-life in humans of 1.5 to 2.0 hours. [7] [8] [9] Two hours following attainment of peak concentrations, levels of gaboxadol are reduced by about 50% in humans. [5] In rodents, the half-life of gaboxadol was about twice as long as that of muscimol. [70] In people with severe renal impairment, circulating levels of gaboxadol were increased by 5-fold, and the renal clearance of gaboxadol was decreased by 34% while that of gaboxadol-O-glucuronide was decreased by 50%. [4]

Chemistry

Gaboxadol, also known by its chemical name 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), is a conformationally constrained synthetic analogue of the major inhibitory neurotransmitter γ-aminobutyric acid (GABA) and of the Amanita alkaloid muscimol. [14]

Properties

Gaboxadol is a zwitterion, with pKa values of 4.3 (acidic) and 8.3 (basic) and a log P value of –0.61. [55] [80] It was formulated pharmaceutically as the hydrochloride salt. [80] The compound's solubility is greater than 30 mg/mL at physiological pH. [80]

Synthesis

The chemical synthesis of gaboxadol has been described. [1] [81] [82] Its synthesis has been described as tedious, starting with a commercially unavailable precursor, requiring at least 6 synthetic steps, and having very low yields. [13] This has limited the affordability and availability of gaboxadol. [13]

Analogues

Analogues of gaboxadol (THIP) include γ-aminobutyric acid (GABA), muscimol, 4-AHP, thio-THIP, aza-THIP, iso-THIP, THAZ, THPO, piperidine-4-sulfonic acid (P4S), isonipecotic acid, and isoguvacine, among others. [19] [31] [55] [83] Numerous attempts to develop pharmacologically interesting analogues of gaboxadol have failed over the decades. [84] This can be attributed to the very strict structural requirements for GABAA receptor binding and activation. [14] As such, gaboxadol has been described as a unique compound and GABAA receptor agonist. [84]

History

Gaboxadol was first synthesized and described by the Danish chemist Povl Krogsgaard-Larsen in 1977. [1] [13] [84] [20] It was developed via structural modification of muscimol, a constituent of Amanita muscaria mushrooms. [19] [17] [18] In the early 1980s, the drug was the subject of a series of small pilot clinical studies that evaluated it in the treatment of various medical conditions, but it was not found to be useful. [13]

In 1996, a somnologist named Marike Lancel at the Max Planck Institute for Psychiatry studied the effects of gaboxadol on sleep in rodents and found that it had unique positive effects on sleep, such as increased slow wave sleep. [13] [84] [50] [85] In 1997, Lancel and colleagues published the first clinical study of the effects of gaboxadol on sleep in humans and found similar sleep improvements as in rodents. [11] [13] [86] Subsequently, gaboxadol underwent formal clinical development for treatment of insomnia by Lundbeck and Merck. [2] [13] [1] [82] It reached phase 3 trials for this indication by at least 2004. [1] The drug was expected to be a blockbuster drug for its pharmaceutical developers. [87] [50] [26]

In 2007, the development of gaboxadol was terminated by Lundbeck and Merck. [2] [26] [48] They cited lack of effectiveness in a large 3-month clinical trial, the occurrence of high rates of psychiatric adverse effects at supratherapeutic doses in a misuse liability study with drug users, a frequent incidence of tachycardia at therapeutic doses, and other reasons. [13] [26] [3] [27] Moreover, there was anxiety in the pharmaceutical industry concerning hypnotics at the time owing to bizarre reports of zolpidem (Ambien)-induced delirium that had emerged in the media in 2006. [13] This may have resulted in greater concern about potential liability issues. [13] Merck was also struggling with recent litigation from its drug rofecoxib (Vioxx), which may have made it further averse to liability. [13] [50] When presented with the data on the hallucinogenic effects of high doses of gaboxadol, a Merck executive remarked "looks like LSD to me!" [50] A New Drug Application (NDA) was ultimately never submitted to the United States Food and Drug Administration (FDA). [50] [48] [26] Many of the companies' employees were said to have been surprised and confused by the discontinuation [41] and the decision is still critically debated. [84]

Journalist and scientist Hamilton Morris wrote and published a notable exposé on gaboxadol in Harper's Magazine in 2013, including his self-experimentation with the drug. [12] [15] [13] According to Morris, the discontinuation of gaboxadol's late-stage development may have deprived people with insomnia access to an effective, safe, and non-addictive treatment. [13] In addition, Morris has critiqued the pharmaceutical industry as being more interested in selling minimally effective drugs devoid of side effects instead of medications with real therapeutic effects but a higher risk of litigation. [13]

In 2015, Lundbeck sold its rights to the molecule to Ovid Therapeutics, whose plan was to develop it for Angelman syndrome (AS) and fragile X syndrome (FXS). [2] [88] It was known internally at Ovid Therapeutics under the developmental code name OV101. [2] In 2021, development of gaboxadol for Angelman syndrome and fragile X syndrome was discontinued due to lack of effectiveness. [2] [23] [89]

Society and culture

Names

Gaboxadol is the generic name of the drug and its INN Tooltip International Nonproprietary Name and USAN Tooltip United States Adopted Name. [1] [90] It is also known by its former developmental code names Lu-2-030 or Lu-02-030 (Lundbeck), MK-0928 (Merck), and OV101 (Ovid Therapeutics). [1] [2] In addition, gaboxadol is well-known in the scientific literature by its chemical name 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP). [14] [54]

Media coverage

Gaboxadol was covered, along with muscimol and Amanita muscaria , in an episode of Hamilton Morris's Hamilton's Pharmacopeia . [42] [91]

Notable individuals

Povl Krogsgaard-Larsen and Hamilton Morris have both self-experimented with gaboxadol. [15] [13] [42] [43] [44] Morris has described gaboxadol as the "perfect hypnotic" and as the "best hypnotic" he'd ever tried, but also found that it produced strong hallucinogenic effects at high doses. [15] [41] [13] [42] [43] [44]

Grey market use

Gaboxadol has been obtained rarely from the grey market, for instance from China, for hypnotic and hallucinogenic purposes. [13] [41] [42] [43] [44]

The closely related GABAA receptor agonist muscimol, found in Amanita muscaria mushrooms, has been reported to induce sleep in humans similarly to gaboxadol, in addition to its well-known hallucinogenic effects that occur at higher doses. [18] [92] While gaboxadol was never approved for medical use, informal microdosing of muscimol and Amanita mushrooms for improvement of sleep has become increasingly prevalent by the mid-2020s. [18] [93] [94] However, muscimol is far less-researched compared to gaboxadol, [18] and is less selective and said to be much more toxic in comparison. [55] [19] [71] [13] In addition, Amanita mushrooms contain other pharmacologically active compounds besides muscimol, such as the glutamate receptor agonist and neurotoxin ibotenic acid and the muscarinic acetylcholine receptor agonist and parasympathomimetic muscarine, which are liable to pose toxicity risks as well. [95] [42] Povl Krogsgaard-Larsen has warned about safety concerns with regard to medicinal use of Amanita mushrooms. [42]

Gaboxadol is not a controlled substance anywhere in the world as of October 10, 2025. [50] [26] [27]

Research

Gaboxadol was studied in the 1980s by Lundbeck and others in the treatment of a variety of medical conditions, [84] [11] [15] [14] [13] including pain, [96] anxiety, [8] mania, [97] schizophrenia and tardive dyskinesia, [98] [99] epilepsy, [100] Huntington's disease, [101] and Alzheimer's disease. [102] It showed poor clinical effectiveness as an anticonvulsant, in accordance with prior animal studies. [84] [100] In addition, it had only weak anxiolytic effects in humans and at doses that were accompanied by substantial side effects. [84] [8] On the other hand, gaboxadol was found to be an effective analgesic in some patients and was equipotent to morphine in these individuals. [84] Moreover, it lacked the respiratory depression and other characteristic adverse effects of morphine. [84] However, gaboxadol was ultimately not further developed due to its pronounced sedative and other side effects. [84] [8]

Later on, in the 1990s and 2000s, gaboxadol was developed for the treatment of insomnia and reached phase 3 clinical trials for this indication. [11] [1] [86] [13] However, development was discontinued in 2007 for safety and effectiveness reasons. [2] [3] [15] [13] Multiple large phase 3 trials were completed and published. [15] [35] [21] [27] As a result, gaboxadol was not approved and will likely never be used as a hypnotic commercially. [15] There has been some further study of gaboxadol as a hypnotic by David Nutt and colleagues after the discontinuation of its development. [103] [104] The drug was also studied for treatment of major depressive disorder in combination with escitalopram in a phase 2 trial, but was ineffective. [105] [13] [106]

Following discontinuation of its development for insomnia, gaboxadol was repurposed by Ovid Therapeutics for treatment of the Angelman syndrome and fragile X syndrome. [2] [12] [107] [108] [109] It reached phase 3 and phase 2 clinical trials for these conditions, respectively. [2] [109] [107] However, development was discontinued for these uses as well in 2021. [2] [23] [89] The drug is no longer under development for any indication. [2]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Sorbera LA, Castaner J, Silvestre JS (2004). "Gaboxadol" . Drugs of the Future. 29 (5): 0449. doi:10.1358/dof.2004.029.05.803754 . Retrieved 19 June 2025.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Gaboxadol - Lundbeck A/S". AdisInsight. 15 March 2023. Retrieved 14 February 2025.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Frølund S, Nøhr M, Holm R, Brodin B, Nielsen C (2013). "Potential involvement of the proton-coupled amino acid transporter PAT1 (SLC36A1) in the delivery of pharmaceutical agents". Journal of Drug Delivery Science and Technology. 23 (4): 293–306. doi:10.1016/S1773-2247(13)50046-3 . Retrieved 4 October 2025. Gaboxadol is a bicyclic analogue of the neurotransmitter GABA. Pharmacologically, gaboxadol acts as a selective extra-synaptic GABAA receptor agonists (SEGA) and was the first compound identified in a novel class of sleep agents [68]. The drug development of gaboxadol, with the indication for treatment of primary insomnia, was discontinued in 2007, partly due to the lack of efficacy observed in a large 3-month efficacy and safety study conducted in the United States [65], and partly due to the occurrence of psychiatric side effect at supra-therapeutic doses in an abuse liability study involving drug abusers [69, 70]. Early preclinical studies in rat, mouse, and human have shown that the absorption of gaboxadol is fast and almost complete (84-96 %) [71, 72]. As gaboxadol is a zwitterionic compound with pKa values of 4.31 and 8.13 [46] and a logDpH 7.4 value of -2.37 (unpublished data), the physicochemical data of the compound indicates that the intestinal transport may require the action of one or more membrane transporters. Also, the plasma protein binding of gaboxadol is low (< 15 %) in rodents [73] and less than 2 % in humans [74].
  4. 1 2 3 4 5 6 7 8 Chu XY, Liang Y, Cai X, Cuevas-Licea K, Rippley RK, Kassahun K, et al. (February 2009). "Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters". Pharmaceutical Research. 26 (2): 459–468. doi:10.1007/s11095-008-9799-5. PMID   19082692.
  5. 1 2 3 4 5 6 Krogsgaard-Larsen P (1984). "THIP, a specific and clinically active GABA agonist". Neuropharmacology. 23 (7): 837–838. doi:10.1016/0028-3908(84)90272-7 . Retrieved 22 September 2025.
  6. 1 2 3 4 5 6 7 Deacon S, Staner L, Staner C, Legters A, Loft H, Lundahl J (March 2007). "Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia". Sleep. 30 (3): 281–287. doi:10.1093/sleep/30.3.281. PMID   17425224. When given orally in healthy subjects, gaboxadol is rapidly absorbed (tmax of 30-60 min) and eliminated (t½ of 1.5 h). More than 95% of the dose is excreted in the urine, mostly unchanged. A glucoronide conjugate is the only metabolite formed in significant amounts. Hence the CYP450 system does not have significant involvement in the metabolism of gaboxadol.
  7. 1 2 3 Lund, J., Helboe, T., & Mengel, H. (2006, January). Absorption, metabolism and excretion profile of gaboxadol in humans. In Sleep (Vol. 29, pp. A41-A41). https://scholar.google.com/scholar?cluster=17960150700023416661
  8. 1 2 3 4 5 6 7 8 9 Hoehn-Saric R (1983). "Effects of THIP on chronic anxiety". Psychopharmacology. 80 (4): 338–341. doi:10.1007/BF00432116. PMID   6414002. THIP, a 4,5,6,7-tetrahydroisoxazolo(5,4-C)pyridin-3-ol, is a muscimol analog which exhibits specific GABA-agonists properties without affecting enzymes involved in the synthesis or the catabolism of the neurotransmitter. It is 5–15-times weaker than muscimol and substantially less toxic. THIP penetrates the blood–brain barrier and has a half-life of 1.5–2 h (H Lundbeck and Company 1981).
  9. 1 2 Madsen SM, Lindeburg T, Følsgård S, Jacobsen E, Sillesen H (November 1983). "Pharmacokinetics of the gamma-aminobutyric acid agonist THIP (Gaboxadol) following intramuscular administration to man, with observations in dog". Acta Pharmacologica et Toxicologica. 53 (5): 353–357. doi:10.1111/j.1600-0773.1983.tb03434.x. PMID   6659963. The dose-group mean values of k correspond to an elimination half-life of 1.39 hr and 1.33 hr after the dose of 10 or 20 mg THIP-monohydrate, respectively.
  10. 1 2 3 Schultz B, Aaes-Jørgensen T, Bøgesø KP, Jørgensen A (August 1981). "Preliminary studies on the absorption, distribution, metabolism, and excretion of THIP in animal and man using 14C-labelled compound". Acta Pharmacologica et Toxicologica. 49 (2): 116–124. doi:10.1111/j.1600-0773.1981.tb00879.x. PMID   7336969.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Wafford KA, Ebert B (February 2006). "Gaboxadol--a new awakening in sleep". Current Opinion in Pharmacology. 6 (1): 30–36. doi:10.1016/j.coph.2005.10.004. PMID   16368265.
  12. 1 2 3 4 Brickley SG, Franks NP, Wisden W (2018). "Modulation of GABA A receptor function and sleep" (PDF). Current Opinion in Physiology. 2: 51–57. doi: 10.1016/j.cophys.2017.12.011 . Archived from the original (PDF) on 27 April 2019. Retrieved 5 October 2025.
  13. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Morris H (August 2013). "Gaboxadol". Harper's Magazine. Retrieved 2014-11-20.
  14. 1 2 3 4 5 6 7 8 9 Krogsgaard-Larsen P, Frølund B, Liljefors T (2006). "GABAA Agonists and Partial Agonists: THIP (Gaboxadol) as a Non-Opioid Analgesic and a Novel Type of Hypnotic1". GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Adv Pharmacol. Vol. 54. pp. 53–71. doi:10.1016/s1054-3589(06)54003-7. ISBN   978-0-12-032957-1. PMID   17175810. In cancer patients and also in patients with chronic anxiety (Hoehn‐Saric, 1983) the desired effects of Gaboxadol were accompanied by side effects, notably sedation, nausea, and in a few cases euphoria. The side effects of Gaboxadol have, however, been described as mild and similar in quality to those of other GABA‐mimetics (Hoehn‐Saric, 1983). This combination of analgesic and anxiolytic effects of THIP obviously has therapeutic prospects. [...]
  15. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Wisden W, Yu X, Franks NP (2019). "GABA Receptors and the Pharmacology of Sleep". Handbook of Experimental Pharmacology. 253: 279–304. doi:10.1007/164_2017_56. ISBN   978-3-030-11270-7. PMID   28993837.
  16. 1 2 3 4 5 6 7 8 9 Atack JR (2010). "Development of Subtype-Selective GABAA Receptor Compounds for the Treatment of Anxiety, Sleep Disorders and Epilepsy". GABA and Sleep. Basel: Springer Basel. pp. 25–72. doi:10.1007/978-3-0346-0226-6_2. ISBN   978-3-0346-0225-9 . Retrieved 4 October 2025.
  17. 1 2 3 4 5 6 7 Johnston GA (October 2014). "Muscimol as an ionotropic GABA receptor agonist". Neurochemical Research. 39 (10): 1942–1947. doi:10.1007/s11064-014-1245-y. PMID   24473816. The effects of THIP on sleep resembled those reported earlier for muscimol and were dissimilar from those induced by benzodiazepine modulators of GABAA receptors [45].
  18. 1 2 3 4 5 Rivera-Illanes D, Recabarren-Gajardo G (September 2024). "Classics in Chemical Neuroscience: Muscimol". ACS Chemical Neuroscience. 15 (18): 3257–3269. doi:10.1021/acschemneuro.4c00304. PMID   39254100.
  19. 1 2 3 4 5 6 7 Krogsgaard-Larsen P, Frølund B, Liljefors T, Ebert B (October 2004). "GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic". Biochemical Pharmacology. 68 (8): 1573–1580. doi:10.1016/j.bcp.2004.06.040. PMID   15451401. Similar [sleep] results [relative to gaboxadol] have been obtained with muscimol, with the GABA uptake inhibitor Tiagabine [65], and with the glia-selective GABA uptake inhibitor, THPO (Fig. 2) [66] [...]
  20. 1 2 Krogsgaard-Larsen P, Johnston GA, Lodge D, Curtis DR (July 1977). "A new class of GABA agonist". Nature. 268 (5615): 53–55. Bibcode:1977Natur.268...53K. doi:10.1038/268053a0. PMID   196200.
  21. 1 2 3 4 5 6 7 8 9 10 Roth T, Lines C, Vandormael K, Ceesay P, Anderson D, Snavely D (February 2010). "Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies". Journal of Clinical Sleep Medicine. 6 (1): 30–39. doi:10.5664/jcsm.27707. PMC   2823273 . PMID   20191935. Gaboxadol is no longer in clinical development for the treatment of insomnia based on an assessment of its overall clinical profile in phase 3 trials, including those reported here, which suggested limited or variable efficacy, and also the occurrence of psychiatric side effects at supra-therapeutic doses in an abuse liability study involving drug abusers.11,12 [...] 11. Lundbeck. Discontinuation of development program for gaboxadol in insomnia. H. Lundbeck website. [...] March 27, 2007. Accessed May 26, 2009. 12. Schoedel KA, Rosen LB, Alexander R, et al. A single-dose randomized, double-blind, crossover abuse liability study to evaluate the subjective and objective effects of gaboxadol and zolpidem in recreational drug users. Clin Pharmacol Ther 2009; 85 (Suppl 1):S22. Abstract PI-44.
  22. ↑ Heussler HS (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome". Current Opinion in Psychiatry. 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. PMID   33395098.
  23. 1 2 3 Shapiro L (23 August 2023). "Final trial data support Ovid's decision to stop OV101 program in..." Angelman Syndrome News. Retrieved 4 October 2025.
  24. ↑ Lloyd KG, Morselli PL, Depoortere H, Fournier V, Zivkovic B, Scatton B, et al. (June 1983). "The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials". Pharmacology, Biochemistry, and Behavior. 18 (6): 957–966. doi:10.1016/s0091-3057(83)80021-5. PMID   6351106. Recently interest has taken hold on the possibility that GABA systems may play a role in affective disorders. The major impetus for this effort has been the demonstration that one GABA agonist (progabide) has antidepressant qualities (see below) and that another GABA agonist (THIP) is mood elevating (Krogsgaard-Larsen, personal communication).
  25. 1 2 3 4 5 Schoedel KA, Rosen LB, Alexander R, Wang J, Snavely D, Murphy MG, et al. (16 January 2009). "Poster Session I (PI 1-89): PI-44: A single-dose randomized, double-blind, crossover abuse liability study to evaluate the subjective and objective effects of gaboxadol and zolpidem in recreational drug users". Clinical Pharmacology & Therapeutics. 85 (S1 [Supplement: Abstracts of the 2009 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. National Harbor, Maryland, USA. March 18–21, 2009]): S9–S36 (S22–S22). doi:10.1038/sj.clpt.2008.283. ISSN   0009-9236.
  26. 1 2 3 4 5 6 7 8 9 "Merck, Lundbeck scrap insomnia drug after trials". Reuters. 9 August 2007. Retrieved 30 September 2025.
  27. 1 2 3 4 5 6 Lundbeck (28 March 2007). "Discontinuation of development program for gaboxadol in insomnia: Teleconference 28 March 2007" (PDF). Archived from the original (PDF) on 17 October 2007.
  28. 1 2 Dijk DJ, Landolt HP (2019). "Sleep Physiology, Circadian Rhythms, Waking Performance and the Development of Sleep-Wake Therapeutics". Handbook of Experimental Pharmacology. 253: 441–481. doi:10.1007/164_2019_243. ISBN   978-3-030-11270-7. PMID   31254050. Agonists of the extra-synaptic GABAA receptor such as gaboxadol, also known as THIP, reliably induce SWS and SWA in healthy participants at baseline, in a model of transient insomnia (traffic noise, Dijk et al. 2012), a model of sleep onset insomnia (Mathias et al. 2001), a circadian phase advance model (Walsh et al. 2007), older participants (Lancel et al. 2001) and insomnia patients (Lankford et al. 2008). Interestingly, the effects of gaboxadol on sleep are much stronger in women than in men (Dijk et al. 2010b; Ma et al. 2011; Roth et al. 2010).
  29. 1 2 3 Walsh JK (April 2009). "Enhancement of slow wave sleep: implications for insomnia". Journal of Clinical Sleep Medicine. 5 (2 Suppl): S27 –S32. doi:10.5664/jcsm.5.2S.S27. PMC   2824211 . PMID   19998872.
  30. ↑ Dijk DJ, Stanley N, Lundahl J, Groeger JA, Legters A, Trap Huusom AK, et al. (August 2012). "Enhanced slow wave sleep and improved sleep maintenance after gaboxadol administration during seven nights of exposure to a traffic noise model of transient insomnia". Journal of Psychopharmacology. 26 (8): 1096–1107. doi:10.1177/0269881111421971. PMID   22002961.
  31. 1 2 3 Krogsgaard-Larsen P, Frølund B, Liljefors T (2002). "Specific GABA(A) agonists and partial agonists". Chemical Record. 2 (6): 419–430. doi:10.1002/tcr.10040. PMID   12469353.
  32. ↑ Mathias S, Zihl J, Steiger A, Lancel M (April 2005). "Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects". Neuropsychopharmacology. 30 (4): 833–841. doi:10.1038/sj.npp.1300641. PMID   15602499.
  33. ↑ Walsh JK, Snyder E, Hall J, Randazzo AC, Griffin K, Groeger J, et al. (May 2008). "Slow wave sleep enhancement with gaboxadol reduces daytime sleepiness during sleep restriction". Sleep. 31 (5): 659–672. doi:10.1093/sleep/31.5.659. PMC   2398757 . PMID   18517036.
  34. ↑ Lancel M, Langebartels A (June 2000). "gamma-aminobutyric Acid(A) (GABA(A)) agonist 4,5,6, 7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol persistently increases sleep maintenance and intensity during chronic administration to rats". The Journal of Pharmacology and Experimental Therapeutics. 293 (3): 1084–1090. doi:10.1016/S0022-3565(24)39335-8. PMID   10869413.
  35. 1 2 Lankford DA, Corser BC, Zheng YP, Li Z, Snavely DB, Lines CR, et al. (October 2008). "Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies". Sleep. 31 (10): 1359–1370. PMC   2572741 . PMID   18853933.
  36. ↑ Dijk DJ (June 2010). "Slow-wave sleep deficiency and enhancement: implications for insomnia and its management". The World Journal of Biological Psychiatry. 11 (Suppl 1): 22–28. doi:10.3109/15622971003637645. PMID   20509829.
  37. ↑ Boyle J, Wolford D, Gargano C, McCrea J, Cummings C, Cerchio K, et al. (January 2009). "Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects". Human Psychopharmacology. 24 (1): 61–71. doi:10.1002/hup.986. PMID   18985628.
  38. 1 2 3 4 5 6 7 McDonald LM, Sheppard WF, Staveley SM, Sohal B, Tattersall FD, Hutson PH (March 2007). "Gaboxadol, a selective extrasynaptic GABA(A) agonist, does not generalise to other sleep-enhancing drugs: a rat drug discrimination study". Neuropharmacology. 52 (3): 844–853. doi:10.1016/j.neuropharm.2006.10.009. PMID   17196996. In studies from other laboratories, gaboxadol (5.6 mg/kg i.p. training dose) did not generalise to midazolam (Ator, 1991), and rats trained to discriminate lorazepam (1 mg/kg i.p.), midazolam (0.4 mg/kg s.c.) or diazepam (2.5 mg/kg i.p.) from vehicle did not generalise to gaboxadol (Nielsen et al., 1983; Ator and Griffiths, 1986; Rauch and Stolerman, 1987). Gaboxadol showed partial generalisation to pentobarbital (5 or 10 mg/kg i.p. training dose) in two studies (Ator and Griffiths, 1986; Grech and Balster, 1993). The only compound to which gaboxadol has fully generalised is the GABAA agonist, muscimol (1 mg/kg i.p. training dose; Grech and Balster, 1997; Jones and Balster, 1998). [...] For example, zolpidem, indiplon, RS-zopiclone and S-zopiclone were all reported to enhance sleep onset and increase the total duration of sleep (Nakajima et al., 2000; Zammit et al., 2004; Swainston Harrison and Keating, 2005; Thomson Scientific, 2006). Gaboxadol did not affect sleep onset and had no effect on rapid eye movement (REM) sleep, but increased the total duration of slow-wave sleep in rats (Lancel and Faulhaber, 1996), which resembled the changes it induces in human sleep (Faulhaber et al., 1997). Muscimol had similar effects to gaboxadol on sleep in rats, although it also increased REM sleep (Lancel et al., 1996).
  39. 1 2 Ebert B (February 2009). "Discontinued drugs 2007: central and peripheral nervous system drugs". Expert Opinion on Investigational Drugs. 18 (2): 109–123. doi:10.1517/13543780802687371. PMID   19236259.
  40. 1 2 Wafford KA, Ebert B (June 2008). "Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time". Nature Reviews. Drug Discovery. 7 (6): 530–540. doi:10.1038/nrd2464. PMID   18511929.
  41. 1 2 3 4 Thulin L (7 August 2013). "Speaking with Psychonaut Hamilton Morris about sleep". New York Daily News. Retrieved 4 October 2025.
  42. 1 2 3 4 5 6 7 Morris H (9 January 2018). "A Fungal Fairy Tale". Hamilton's Pharmacopeia . Season 2. Episode 7. Vice Media. Viceland.
  43. 1 2 3 4 5 Hamilton Morris (25 December 2021). "PODCAST 36: An Amanita Christmas with Dr. Povl Krogsgaard-Larsen". The Hamilton Morris Podcast (Podcast). Patreon. Event occurs at ~48:00, ~2:07:30. Retrieved 14 February 2025. [Morris:] [...] they did produce enough [gaboxadol] [...] to conduct a number of self-experiments, some at very high doses. He experienced extremely dramatic psychedelic effects at those high doses. [...] I have a written report—I mentioned that I had a friend [...] [a]nd he took a very, very large dose of [gaboxadol] [...] it was 63 mg of the zwitterion. [...] It's you know very, very dramatic hallucinogenic effects. He describes his entire reality being fragmented. [...]
  44. 1 2 3 4 5 6 Hamilton Morris (29 December 2022). "POD 65: Dr. Andrew Gallimore on DMTx and Reality Switch Technologies". The Hamilton Morris Podcast (Podcast). Patreon. Event occurs at 1:02:16–1:04:33. Retrieved 21 March 2025. [Morris:] I've used high doses of gaboxadol and that is as psychedelic as anything else. It's different, of course. It's a different type of experience entirely. But that same sort of proliferation of ideas and perceptual disturbances is very much present. It is not in any way analogous to a benzodiazepine. It's something that is visionary and completely alien and strange. [...] It's worth trying. Not because it's enjoyable or good. It's also not bad either. [...] the most intense gaboxadol experience of my life was in Japan. [...] [I was like] at night I'm gonna take gaboxadol at a high dose to knock myself out. And I'd taken gaboxadol at lower doses many many times before and I'd had mild effects from it. [...] [Due to jet lag] I was much more awake and alert and unintentionally had one of the most intense psychedelic experiences of my life taking this stuff that I was thinking was just going to knock me out. [...] I spent the entire night in this visionary state trying to figure out a way to lose consciousness but instead I was hyperconscious [...]
  45. 1 2 3 Joe Rogan (26 June 2018). "Joe Rogan Experience #1136". YouTube (Podcast). The Joe Rogan Experience. Archived from the original on 26 June 2018. [Gaboxadol is] every bit as powerful as ayahuasca or something like that, but completely different. [...] it's something that's been experienced by relatively few people, so you don't even have this spiritual or metaphorical vocabulary for it. [...] So I took a high dose I believe it was 45 [mg], but don't quote me on that, of [gaboxadol]. [...] And it was unbelievable. I mean, I couldn't fathom the intensity of what I experienced. It was, you know, just this rushing sense of becoming a passive observer in my own consciousness and seeing all of my thoughts produced by someone else that were racing at a speed that was so fast that I found it physically dizzying and had to lay down. And I felt as if the acceleration was pushing me toward an ultimate state that was sleep and that sleep and death represented the ultimate state of consciousness. [...] [I had this] transformative existential trip accidentally [...] Did you ever recreate that kind of experience? No, because it was, it was a bit much, I would say. And I know people that have taken even more, and it turns into just your entire visual field transforming into rotating cubes where each face of the cube represents a different aspect of your life, your future, your past, your present, you know, really dramatic stuff. [...]
  46. 1 2 Magazine H (23 July 2013). "Writers Go in Search of a Good Night's Sleep, by Harper's Magazine". Harper's Magazine. Retrieved 4 October 2025. "I heard about gaboxadol and decided I had to try it," writes Hamilton Morris of a rare chemical remedy for insomnia that, though it is nowhere near being approved by the U.S. Food and Drug Administration, could be an improvement over Ambien, Valium, and Xanax. But what really appeals to Morris is the hallucinogenic delirium gaboxadol is said to induce. The intrepid reporter scores some: "In my darkened bedroom," he writes, "I could hear otherworldly music emanating from the motor of a box fan, the white-noise buzzing slowing, taking on the character of an electric viola, the room's various shadows animated by strange movements as if cast by a flickering candle—but none of this proved distracting." Morris finds that gaboxadol is indeed the perfect hypnotic.
  47. ↑ Lu C, Geng Y, Guan X, Meng Y, Zhu M, Zhao Y (2025). "Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis". Frontiers in Psychiatry. 16 1461166. doi: 10.3389/fpsyt.2025.1461166 . PMC   12283787 . PMID   40704033.
  48. 1 2 3 "Merck & Co and Lundbeck's sleep drug terminated in Phase III". PharmaTimes. 29 March 2007. Retrieved 5 October 2025. The firms said they are discontinuing studies of the because data from recently-completed Phase III studies suggest that the overall clinical profile for gaboxadol in insomnia does not support further development. As a result of this new information, Merck and Lundbeck added that they will not file gaboxadol with the US Food and Drug Administration, or any other regulatory agencies worldwide, and are terminating the project. [...] "new safety data showed a dramatic increase in psychiatric adverse events at doses as low as twice the recommended dose, raising the possibility of real safety issues in sleep-drug abusers." Although earlier trials showed effectiveness in sleep onset and maintenance, the drug failed to do either in the latest trials, Mr Tooley wrote, noting that a recent sleep lab study failed to show sufficient effects at lower doses.
  49. ↑ Skerritt JH, Johnston GA (August 1983). "Diazepam stimulates the binding of GABA and muscimol but not THIP to rat brain membranes". Neuroscience Letters. 38 (3): 315–320. doi:10.1016/0304-3940(83)90388-9. PMID   6314189.
  50. 1 2 3 4 5 6 7 Miller R (2013). Drugged: The Science and Culture Behind Psychotropic Drugs. EBL ebooks online. Oxford University Press. ISBN   978-0-19-995798-9 . Retrieved 5 October 2025.
  51. ↑ Stórustovu S, Ebert B (April 2003). "Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity". European Journal of Pharmacology. 467 (1–3): 49–56. doi:10.1016/s0014-2999(03)01603-0. PMID   12706454.
  52. ↑ Voss J, Sanchez C, Michelsen S, Ebert B (December 2003). "Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance". European Journal of Pharmacology. 482 (1–3): 215–222. doi:10.1016/j.ejphar.2003.10.007. PMID   14660025.
  53. ↑ Johnston GA (2005). "GABA(A) receptor channel pharmacology". Current Pharmaceutical Design. 11 (15): 1867–1885. doi:10.2174/1381612054021024. PMID   15974965.
  54. 1 2 3 Christensen AV, Svendsen O, Krogsgaard-Larsen P (October 1982). "Pharmacodynamic effects and possible therapeutic uses of THIP, a specific GABA-agonist". Pharmaceutisch Weekblad. Scientific Edition. 4 (5): 145–153. doi:10.1007/BF01959034. PMID   6292818.
  55. 1 2 3 4 5 6 7 8 Frølund B, Ebert B, Kristiansen U, Liljefors T, Krogsgaard-Larsen P (August 2002). "GABA(A) receptor ligands and their therapeutic potentials". Current Topics in Medicinal Chemistry. 2 (8): 817–832. doi:10.2174/1568026023393525. PMID   12171573. The fact that muscimol is a non-specific GABAA receptor agonist [38, 39], a substrate for the GABA-metabolizing enzyme, GABA transaminase [40], and moreover a neurotoxin, makes the compound therapeutically less valuable. [...] Further conformational restriction of the GABA structural element in muscimol has been achieved by incorporating the amino group into a piperidine ring leading to the bicyclic analogue, THIP, a specific GABAA agonist [11]. THIP has been shown to be devoid of the neurotoxic properties of muscimol and, in contrast to muscimol, is metabolically stable.
  56. 1 2 Ebert B, Mortensen M, Thompson SA, Kehler J, Wafford KA, Krogsgaard-Larsen P (June 2001). "Bioisosteric determinants for subtype selectivity of ligands for heteromeric GABA(A) receptors". Bioorganic & Medicinal Chemistry Letters. 11 (12): 1573–1577. doi:10.1016/s0960-894x(01)00184-6. PMID   11412984.
  57. ↑ Brown N, Kerby J, Bonnert TP, Whiting PJ, Wafford KA (August 2002). "Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors". British Journal of Pharmacology. 136 (7): 965–974. doi:10.1038/sj.bjp.0704795. PMC   1573424 . PMID   12145096.
  58. ↑ Orser BA (2006-04-15). "Extrasynaptic GABAA Receptors Are Critical Targets for Sedative-Hypnotic Drugs". Journal of Clinical Sleep Medicine. 02 (2). doi: 10.5664/jcsm.26526 . ISSN   1550-9389.
  59. 1 2 3 Johnston GA (October 2014). "Muscimol as an ionotropic GABA receptor agonist". Neurochemical Research. 39 (10): 1942–1947. doi:10.1007/s11064-014-1245-y. PMID   24473816.
  60. ↑ Rudolph U, Knoflach F (July 2011). "Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes". Nature Reviews. Drug Discovery. 10 (9): 685–697. doi:10.1038/nrd3502. PMC   3375401 . PMID   21799515.
  61. ↑ Mortensen M, Ebert B, Wafford K, Smart TG (April 2010). "Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABAA receptors". The Journal of Physiology. 588 (Pt 8): 1251–1268. doi:10.1113/jphysiol.2009.182444. PMC   2872731 . PMID   20176630.
  62. ↑ Winsky-Sommerer R, Vyazovskiy VV, Homanics GE, Tobler I (March 2007). "The EEG effects of THIP (Gaboxadol) on sleep and waking are mediated by the GABA(A)delta-subunit-containing receptors". The European Journal of Neuroscience. 25 (6): 1893–1899. doi:10.1111/j.1460-9568.2007.05455.x. PMID   17408425.
  63. ↑ Walsh JK, Mayleben D, Guico-Pabia C, Vandormael K, Martinez R, Deacon S (May 2008). "Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial". Sleep Medicine. 9 (4): 393–402. doi:10.1016/j.sleep.2007.06.006. PMID   17765013.
  64. ↑ Lobo IA, Harris RA (July 2008). "GABA(A) receptors and alcohol". Pharmacology, Biochemistry, and Behavior. 90 (1): 90–94. doi:10.1016/j.pbb.2008.03.006. PMC   2574824 . PMID   18423561.
  65. ↑ Santhakumar V, Wallner M, Otis TS (May 2007). "Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition". Alcohol. 41 (3): 211–221. doi:10.1016/j.alcohol.2007.04.011. PMC   2040048 . PMID   17591544.
  66. ↑ Wallner M, Olsen RW (May 2008). "Physiology and pharmacology of alcohol: the imidazobenzodiazepine alcohol antagonist site on subtypes of GABAA receptors as an opportunity for drug development?". British Journal of Pharmacology. 154 (2): 288–298. doi:10.1038/bjp.2008.32. PMC   2442438 . PMID   18278063.
  67. ↑ Houston CM, McGee TP, Mackenzie G, Troyano-Cuturi K, Rodriguez PM, Kutsarova E, et al. (March 2012). "Are extrasynaptic GABAA receptors important targets for sedative/hypnotic drugs?". The Journal of Neuroscience. 32 (11): 3887–3897. doi:10.1523/JNEUROSCI.5406-11.2012. PMC   4620914 . PMID   22423109.
  68. 1 2 3 Waszczak BL, Hruska RE, Walters JR (July 1980). "GABAergic actions of THIP in vivo and vitro: a comparison with muscimol and GABA". European Journal of Pharmacology. 65 (1): 21–29. doi:10.1016/0014-2999(80)90204-6. PMID   7398775. The magnitude of the differences between drug potencies in iontophoretic studies closely paralleled their relative potencies in binding studies, with muscimol approximately 3 times more potent than GABA and 25-40 times more potent than THIP. After systemic (i.v.) administration, however, muscimot was only 3 times more potent than THIP in inhibiting reticulata cell firing, possibly because THIP passes the blood-brain barrier more readily.
  69. ↑ Falch E, Larsson OM, Schousboe A, Krogsgaard-Larsen P (1990). "GABA-A agonists and GABA uptake inhibitors: Structure-activity relationships". Drug Development Research. 21 (3): 169–188. doi:10.1002/ddr.430210304. ISSN   0272-4391 . Retrieved 4 October 2025. The anticonvulsant effects of THIP and muscimol have been compared in a variety of animal models. THIP typically is two to five times weaker than muscimol in suppressing seizure activities.
  70. 1 2 3 4 5 6 7 Moroni F, Forchetti MC, Krogsgaard-Larsen P, Guidotti A (October 1982). "Relative disposition of the GABA agonists THIP and muscimol in the brain of the rat". The Journal of Pharmacy and Pharmacology. 34 (10): 676–678. doi:10.1111/j.2042-7158.1982.tb04702.x. PMID   6128395.
  71. 1 2 3 Krogsgaard-Larsen P, Brehm L, Schaumburg K (1981). "Muscimol, a psychoactive constituent of Amanita muscaria, as a medicinal chemical model structure". Acta Chemica Scandinavica. Series B. 35 (5): 311–324. doi:10.3891/acta.chem.scand.35b-0311. PMID   6274117.
  72. ↑ Christensen T, Bétry C, Mnie-Filali O, Etievant A, Ebert B, Haddjeri N, et al. (October 2012). "Synergistic antidepressant-like action of gaboxadol and escitalopram". European Neuropsychopharmacology. 22 (10): 751–760. doi:10.1016/j.euroneuro.2012.02.001. PMID   22406239.
  73. ↑ Grech DM, Balster RL (February 1997). "The discriminative stimulus effects of muscimol in rats". Psychopharmacology. 129 (4): 339–347. PMID   9085403.
  74. 1 2 Vashchinkina E, Panhelainen A, Aitta-Aho T, Korpi ER (2014). "GABAA receptor drugs and neuronal plasticity in reward and aversion: focus on the ventral tegmental area". Frontiers in Pharmacology. 5: 256. doi: 10.3389/fphar.2014.00256 . PMC   4243505 . PMID   25505414.
  75. 1 2 Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, et al. (April 2012). "GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons". The Journal of Neuroscience. 32 (15): 5310–5320. doi:10.1523/JNEUROSCI.4697-11.2012. PMC   6622081 . PMID   22496576.
  76. ↑ Frølund S, Rapin N, Nielsen CU (February 2011). "Gaboxadol has affinity for the proton-coupled amino acid transporter 1, SLC36A1 (hPAT1)--A modelling approach to determine IC(50) values of the three ionic species of gaboxadol". European Journal of Pharmaceutical Sciences. 42 (3): 192–198. doi:10.1016/j.ejps.2010.11.009. PMID   21112392.
  77. ↑ Larsen M, Holm R, Jensen KG, Brodin B, Nielsen CU (August 2009). "Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan". British Journal of Pharmacology. 157 (8): 1380–1389. doi:10.1111/j.1476-5381.2009.00253.x. PMC   2765307 . PMID   19594759.
  78. ↑ Larsen M, Holm R, Jensen KG, Sveigaard C, Brodin B, Nielsen CU (January 2010). "5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination". European Journal of Pharmaceutical Sciences. 39 (1–3): 68–75. doi:10.1016/j.ejps.2009.10.013. PMID   19900542.
  79. ↑ Cremers T, Ebert B (May 2007). "Plasma and CNS concentrations of Gaboxadol in rats following subcutaneous administration". European Journal of Pharmacology. 562 (1–2): 47–52. doi:10.1016/j.ejphar.2007.01.017. PMID   17362924. Using both methods, we observed that Gaboxadol penetrates the brain extensively. After the initial redistribution of Gaboxadol in plasma and CNS, the concentrations and elimination from these two compartments seemed to follow similar parameters. Since no particular transporters of Gaboxadol over the blood brain barrier have been identified, it is likely that passive diffusion alone can account for the CNS pharmacokinetics. The protein binding that was observed in the present study was below 15%. This is similar to the binding in humans (Lund et al., 2006). When plasma levels are corrected for protein binding, the data further confirm the passive penetration of Gaboxadol in the brain, which is apparent when free plasma and brain levels reach unity after an initial equilibration stage (De Lange et al., 2000). In all, these data, indicate that Gaboxadol readily penetrates the brain and suggest that the concentration determined in the brain is a direct reflection of the concentration available for receptor interaction.
  80. 1 2 3 Kesisoglou F, Balakrishnan A, Manser K (February 2016). "Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption". Journal of Pharmaceutical Sciences. 105 (2): 722–728. Bibcode:2016JPhmS.105..722K. doi:10.1002/jps.24674. PMID   26457884. [Gaboxadol] is a zwitterion with pKa values of 4.3 (acidic) and 8.3 (basic) and log P of –0.61. It is dosed as the hydrochloride (HCl) salt. The compound solubility is more than 30 mg/mL in the physiological pH range.
  81. ↑ Rong, L., & Chang, D. (2007). Synthesis of a novel hypnotic, gaboxadol. Chinese Journal of Medicinal Chemistry, 17(3), 166–. https://scholar.google.com/scholar?q=intitle%3A%22Synthesis+of+a+novel+hypnotic%2C+gaboxadol%22
  82. 1 2 US,Krogsgaard-Larsen P,"Heterocyclic compounds",issued 14 July 1981, assigned to H Lundbeck AS
  83. ↑ Grinberga S, Damgaard M, Andersen V, Jensen AA, Krogsgaard-Larsen P, Nielsen B, et al. (2016). Synthesis and Pharmacological Evaluation of Amidine Containing GABAA Receptor Agonists (PDF). EFMC International Symposium on Medicinal Chemistry Manchester, UK Aug. 28 - Sept. 1, 2016. pp. P278 –P278.
  84. 1 2 3 4 5 6 7 8 9 10 11 Krogsgaard-Larsen P (2018). "THIP/Gaboxadol, a Unique GABA Agonist". Reference Module in Biomedical Sciences. Elsevier. doi:10.1016/b978-0-12-801238-3.97290-8. ISBN   978-0-12-801238-3 . Retrieved 7 October 2025.
  85. ↑ Lancel M (December 1997). "The GABA(A) agonist THIP increases non-REM sleep and enhances non-REM sleep-specific delta activity in the rat during the dark period". Sleep. 20 (12): 1099–1104. doi:10.1093/sleep/20.12.1099. PMID   9493918.
  86. 1 2 Faulhaber J, Steiger A, Lancel M (April 1997). "The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans". Psychopharmacology. 130 (3): 285–291. doi:10.1007/s002130050241. PMID   9151364.
  87. ↑ Saul S (29 March 2007). "Merck Cancels Work on a New Insomnia Medication". The New York Times. Archived from the original on 5 October 2025.
  88. ↑ Tirrell M (16 April 2015). "Former Teva CEO's new gig at Ovid Therapeutics". CNBC. Retrieved 2015-05-06.
  89. 1 2 Pinto V (23 April 2021). "Ovid Stops Development and Testing of OV101 for Fragile X". Fragile X News Today. Retrieved 4 October 2025.
  90. ↑ "GABOXADOL". Inxight Drugs. 15 February 2008. Retrieved 4 October 2025.
  91. ↑ McCarthy B (8 October 2022). "The Trippy Truth About Amanita muscaria, the World's Most Famous Mushroom". DoubleBlind Mag. Retrieved 4 October 2025. Also of interest is Hamilton Morris' Pharmacopeia episode on Amanita and his Harper's article on one of its constituents I didn't cover here, gaboxadol.
  92. ↑ Stebelska K (August 2013). "Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities". Therapeutic Drug Monitoring. 35 (4): 420–442. doi:10.1097/FTD.0b013e31828741a5. PMID   23851905.
  93. ↑ Savickaitė E, Laubner-Sakalauskienė G (2025). "Emerging Risks of Amanita Muscaria: Case Reports on Increasing Consumption and Health Risks". Acta Medica Lituanic. 32 (1): 182–189. doi:10.15388/Amed.2025.32.1.23. PMC   12239171 . PMID   40641545.
  94. ↑ Hartwig J, Kendrick J, Ahmad G, Cook J, Matthews DB, Sharma P (2025). "Exploring User Experiences with Amanita muscaria: A Thematic Analysis of Reddit Online Forum Discussions". Substance Use & Misuse. 60 (7): 952–961. doi:10.1080/10826084.2025.2476141. PMID   40057818. The commonly reported reason for Amanita muscaria use was to improve sleep.
  95. ↑ Michelot D, Melendez-Howell LM (February 2003). "Amanita muscaria: chemistry, biology, toxicology, and ethnomycology" (PDF). Mycol Res. 107 (Pt 2): 131–146. doi:10.1017/s0953756203007305. PMID   12747324.
  96. ↑ Maugh TH (April 1981). "Analgesic from mushrooms begins clinical trials". Science. 212 (4493): 431. doi:10.1126/science.212.4493.431.c. PMID   7010604.
  97. ↑ Emrich HM, Altmann H, Dose M, von Zerssen D (August 1983). "Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report". Pharmacology, Biochemistry, and Behavior. 19 (2): 369–372. doi:10.1016/0091-3057(83)90067-9. PMID   6415677.
  98. ↑ Korsgaard S, Casey DE, Gerlach J, Hetmar O, Kaldan B, Mikkelsen LB (September 1982). "The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist". Archives of General Psychiatry. 39 (9): 1017–1021. doi:10.1001/archpsyc.1982.04290090021005. PMID   6126170.
  99. ↑ Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA (June 1987). "Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment". Archives of General Psychiatry. 44 (6): 522–529. doi:10.1001/archpsyc.1987.01800180032006. PMID   3034188.
  100. 1 2 Petersen HR, Jensen I, Dam M (February 1983). "THIP: a single-blind controlled trial in patients with epilepsy". Acta Neurologica Scandinavica. 67 (2): 114–117. doi:10.1111/j.1600-0404.1983.tb04552.x. PMID   6845976.
  101. ↑ Foster NL, Chase TN, Denaro A, Hare TA, Tamminga CA (May 1983). "THIP treatment of Huntington's disease". Neurology. 33 (5): 637–639. doi:10.1212/wnl.33.5.637. PMID   6221200.
  102. ↑ Mohr E, Bruno G, Foster N, Gillespie M, Cox C, Hare TA, et al. (1986). "GABA-agonist therapy for Alzheimer's disease". Clinical Neuropharmacology. 9 (3): 257–263. doi:10.1097/00002826-198606000-00004. PMID   2872956.
  103. ↑ Nutt DJ (March 2025). "Drug development in psychiatry: 50 years of failure and how to resuscitate it". The Lancet. Psychiatry. 12 (3): 228–238. doi:10.1016/S2215-0366(24)00370-5. PMID   39952266.
  104. ↑ Nutt D, Wilson S, Lingford-Hughes A, Myers J, Papadopoulos A, Muthukumaraswamy S (January 2015). "Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: a study in healthy volunteers". Neuropharmacology. 88: 155–163. doi:10.1016/j.neuropharm.2014.08.017. PMID   25195191.
  105. ↑ Pehrson AL, Sanchez C (2015). "Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants". Drug Design, Development and Therapy. 9: 603–624. doi: 10.2147/DDDT.S62912 . PMC   4307650 . PMID   25653499. Another line of inquiry may be drugs that act as agonists at the GABAA-receptor orthosteric binding site. Although preclinical data suggested that the combination of gaboxadol and escitalopram had synergistic antidepressant-like effects in nonclinical models,90 in a clinical trial 5 and 10 mg gaboxadol did not add any benefit over escitalopram treatment alone.91
  106. ↑ Kasper S, Ebert B, Larsen K, Tonnoir B (July 2012). "Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder". The International Journal of Neuropsychopharmacology. 15 (6): 715–725. doi:10.1017/S146114571100112X. PMID   22008735.
  107. 1 2 Keary C, Bird LM, de Wit MC, Hatti S, Heimer G, Heussler H, et al. (November 2023). "Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study". European Journal of Paediatric Neurology. 47: 6–12. doi:10.1016/j.ejpn.2023.07.008. PMID   37639777.
  108. ↑ Bird LM, Ochoa-Lubinoff C, Tan WH, Heimer G, Melmed RD, Rakhit A, et al. (February 2021). "The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome". Neurology. 96 (7): e1024 –e1035. doi:10.1212/WNL.0000000000011409. PMC   8055330 . PMID   33443117.
  109. 1 2 Budimirovic DB, Dominick KC, Gabis LV, Adams M, Adera M, Huang L, et al. (2021). "Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study". Frontiers in Pharmacology. 12 757825. doi: 10.3389/fphar.2021.757825 . PMC   8531725 . PMID   34690787.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.